Dr. Matthew P. Giannetti is a clinician, clinical investigator, and educator at Harvard Medical School and the Brigham and Women’s Hospital Division of Allergy and Clinical Immunology. He received his B.S.E. in Chemical Engineering from the University of Michigan in 2005, and his M.S.E. in Pharmaceutical Engineering in 2006, from the same University. He then attended medical school at the University of Kentucky College of Medicine and obtained a degree of Doctor of Medicine in 2011. From 2011 to 2014, he was a resident at McGaw Medical Center of Northwestern Memorial Hospital. His clinical and research interests include anaphylaxis and mast cell disorders. He is the associate director of the BWH Mastocytosis Center and treats patients with a variety of mast cell disorders including systemic mastocytosis, cutaneous mastocytosis, hereditary alpha tryptasemia, and mast cell activation syndrome. His research activity includes clinical research testing novel therapies for patients with systemic mastocytosis and translational research investigating the molecular pathways driving mastocytosis and, specifically, spontaneous resolution of cutaneous mastocytosis in children.
Dr. Matthew P. Giannetti is a clinician, clinical investigator, and educator at Harvard Medical School and the Brigham and Women’s Hospital Division of Allergy and Clinical Immunology. He received his B.S.E. in Chemical Engineering from the University of Michigan in 2005, and his M.S.E. in Pharmaceutical Engineering in 2006, from the same University. He then attended medical school at the University of Kentucky College of Medicine and obtained a degree of Doctor of Medicine in 2011. From 2011 to 2014, he was a resident at McGaw Medical Center of Northwestern Memorial Hospital. His clinical and research interests include anaphylaxis and mast cell disorders. He is the associate director of the BWH Mastocytosis Center and treats patients with a variety of mast cell disorders including systemic mastocytosis, cutaneous mastocytosis, hereditary alpha tryptasemia, and mast cell activation syndrome. His research activity includes clinical research testing novel therapies for patients with systemic mastocytosis and translational research investigating the molecular pathways driving mastocytosis and, specifically, spontaneous resolution of cutaneous mastocytosis in children.